Zhang S, Liu X, Fang J
School of Oncology, Beijing Medical University, Beijing, 100036.
Zhonghua Jie He He Hu Xi Za Zhi. 1998 Jun;21(6):355-7.
To recognize the prophylactic effect of rhG-CSF used on infection complications secondary to chemotherapy in patients with lung cancer.
The infection complications and the neutropenia secondary to chemotherapy in 163 cases of lung cancer patients with or without rhG-CSF were retrospectively analyzed.
Rhg-CSF administration reduced the frequency of infection complications, and there was a significant difference(P < 0.005) in the frequency of infection between the G-CSF group's patients (infections incidence 25%) and non-G-CSF group's (56%). The incidence of neutropenia in G-CSF group' patients is obviously less than that in non-G-CSF group's (P < 0.005). The median number of days of the neutropenia (neutrophil count of < 1.0 x 10(9) in G-CSF group(3 days) is less than that in non-G-CSF group(4 days)(P < 0.001). However, there was no significant difference (P > 0.05) between G-CSF group(63%) and non-G-CSF group(76%) in terms of response of the infection complications.
Our data has shown that the administration of rhG-CSF as an adjunct to chemotherapy in patients with lung cancer can accelerate neutrophil recovery and shorten the duration of neutropenia, and lead to reductions in the incidence of infection complications, and also has the potential to increase the amount of cytotoxic chemotherapy and the quantity of life.
